A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma

Chun-Hong Ma, Wen-Sheng Sun, Pei-Kun Tian, Li-Fen Gao, Su-Xia Liu, Xiao-Yan Wang, Li-Ning Zhang, Ying-Lin Cao, Li-Hui Han, Xiao-Hong Liang

INTRODUCTION
A major hurdle in most current gene therapy lies in how to transfer genes to target tissues efficiently and how to obtain therapeutic expression of target genes. The targeting efficacy of gene transfection and expression directly determines whether the gene therapy has high efficiency and whether it is harmful to normal tissues. Therefore, how to enhance the targeting efficacy of gene delivery has become a problem to be solved urgently[1-4].

At present, various gene delivery methods have been used in gene therapy[5-9]. Among them, there are two important methods to achieve tumor-targeting gene therapy: one is receptor-mediated gene delivery; another is the construction of tumor-targeting gene expression vector which utilizes tumor-specific transcription regulatory sequence[10-12]. However, either of them, if used singly, can not really accomplish the tumor-targeting gene therapy.

This paper reported a novel HBV antisense RNA delivery system targeting on hepatocarcinoma cells, named AFP-enhancing 4-element complex. This complex includes four elements: (1) recombinant EB virus vector, pEBAF-as-preS2, in which antisense preS2 gene was cloned under the control of human α-fetoprotein (AFP) promoter and enhancer, enabled preS2 antisense RNA to be expressed specifically in AFP-positive cells; (2) ligand oligopeptide GE7, synthesized according to the putative binding region of epidermal growth factor (EGF) to its receptor (EGFR), could transfer DNA specifically to EGFR positive cells; (3) HA20, a homologue of N-terminus of haemagglutinin of influenza envelope protein, was synthesized and conjugated with polylsine. The above conjugates were organized into the pEBAF-as-preS2, a hepatocarcinoma specific HBV antisense expression vector, to construct a novel HBV antisense RNA delivery system, named AFP-enhancing 4-element complex. Hepatocellular carcinoma HepG2.2.15 cells was used to assay the in vitro inhibition of the complex on HBV. Expression of HBV antigen was assayed by ELISA.

RESULTS: The AFP-enhancing 4-element complex was constructed and DNA was completely trapped at the slot with no DNA migration when the ratio of polypeptide to plasmid was 1:1. The expression of HBsAg and HBeAg of HepG2.2.15 cells was greatly decreased after being transfected by AFP-enhancing 4-element complex. The inhibitory rates were 33.4 % and 58.5 % respectively. RT-PCR showed HBV antisense RNA expressed specifically in liver tumor cells of tumor-bearing nude mice. After 4 injections of AFP-enhancing 4-element complex containing 0.2 μg DNA, the diameter of the tumor was 0.995 cm ± 0.35, which was significantly smaller than that of the control groups (2.215 cm ± 0.25, P < 0.05).

CONCLUSION: AFP-enhancing 4-element complex could deliver HBV antisense RNA targeting on hepatocarcinoma and inhibit both HBV and liver tumor cells in vitro and in vivo.

MATERIALS AND METHODS

Cells and cultures
Hepatocellular carcinoma cell line HepG2.2.15 integrated with whole HBV gene not only can accomplish the transcription and translation of HBV, but also may produce Dane’s particles. This cell line, provided by BeiJing Institute of Medicine and Biology, was cultured in the MEM medium containing 10 % FCS and 380 μg/ml G418. The human hepatocellular carcinoma cell line BEL7402 was cultured in the DMEM medium with 10 % FCS. The human umbilical vein endothelial cell line ECV304 contributed by Chinese Academy of Military Medical science was cultured in the DMEM medium, containing 10 % FCS and diantibiotics. The medium mentioned above were purchased from Hyclone Co. American, serum from GIBCO Co.

Animals
BALB/C nude mice, male, 5-6 weeks of age, were purchased...
from experimental animal center of Tongji medical college, Central China Science and Technology University, WuHan. 1×10^7 HepG2.2.15 cells were transplanted subcutaneously into nude mice and were ready for use when the tumor size reached about 0.5 cm in diameter.

**Plasmid**

HBV preS2 gene (3203-3340) was cloned reversely downward 5.5 kb of AFP promoter and enhancer to construct hepatocarcinoma specific preS2 antisense RNA expression vector. pEBAF-as-preS2 (Figure 1) which could express antisense RNA against preS2 in AFP-positive cells. (published elsewhere).

**Figure 1** Physical map of pEBAF-as-preS2. hepatocarcinoma specific preS2 antisense RNA expression vector, pEBAF-as-preS2 was constructed by inserting HBV preS2 gene (3203-3340) reversely downward the AFP promoter and enhancer (AFP-P/E) of plasmid pEBAF which contains the key element of EB virus duplication (OrP and EBNA-1).

**Synthesis of GE7-PL and HA20-PL**

GE7, a 16-peptide specific to EGFR, and HA20, a homologue of N-terminus of haemagglutinin of influenza viral envelope protein, were synthesized by National Laboratory for Oncogene and Related Genes, Shanghai Cancer Institute. GE7 and HA20 were conjugated with polylysine (PL) respectively (GE7-PL and HA20-PL).

**Preparation of AFP-enhancing 4-element complex**

pEBAF-as-preS2 DNA, GE7-PL and HA20-PL conjugates were respectively mixed dropwise into 10μl of deionized water in different ratios. The mixture was incubated at 25°C for 30 min. A mixture containing 0.2 μg plasmid DNA was analyzed on 1 % agarose gel electrophoresis to examine the retardation of DNA migration, in order to determine the optimal ratio. According to the optimal ratio of DNA to conjugates based on above experiment, the plasmid DNA was mixed dropwise to the conjugates of GE7-PL and HA20-PL and reacted at 25 °C for 30 min. Examine the retardation of DNA by 1 % agarose gel electrophoresis. Then the complex could be used for gene transfection.

**In vitro gene transfer by 4-element complex**

5×10^5 cells were seeded into 0.5 ml medium in each well of a 24 well plate. After cell density reached a confluence of 60 %, the medium was removed and replaced with 0.5 ml of complete medium containing 4-element complex in a quantity equivalent to 0.2 μg DNA. Cells were cultured at 37°C and incubated with 5 % CO₂ overnight, then replaced with fresh complete MEM medium without 4-element complex and cultured at 37°C with 5 % CO₂. 3 days after, the supernatant was collected to detect the HBV antigen. Non-transfected HepG2.2.15 cells were used as negative control.

**Detection of virus antigens**

According to the protocol of antigen detection kit (Lizhu Co. ShenZhen, China), the concentration of HBsAg and HBeAg in the supernatant were detected by ELISA. The results were illustrated with P/N value (P/N=sample A/negative control A; A stands for the amount of light absorbent).

**In vivo gene transfection by AFP-enhancing 4-element complex**

AFP-enhancing 4-element complex containing 0.2 μg DNA were injected into a tail vein of nude mice bearing 0.5 cm tumor. Animals were sacrificed 3 days after injection, then the tumor, liver, spleen, kidney, stomach were dissected and used for extracting the total RNA.

**Extraction of total RNA**

Total RNA was extracted from 5 mm³ fresh mice tissues quantitated by Biophotometer (Eppendorf Co.).

**RT-PCR**

Reverse transcription was performed in 20 μl volume including: 1 μg of total RNA, 4 μl of 5xbuffer, 20 nmol dNTP, 20 Units of RNase inhibitor and 20 Units of Moloney murine leukemia virus (M-MLV) reverse transcriptase. The reverse transcription reaction was performed at 42 °C for 1hr. The products were denatured at 70 °C for 10 min and then preserved at 4 °C. cDNA was used as templates for the amplification of preS2 with primers S2P1 and S2P2. PCR was carried out in 25 μl volume with 1 μl of cDNA, 2.5 μl of 10xbuffer, 0.3 mmol Mg²⁺, 5nmol/L dNTP, 3 Units of Taq polymerase, 10 nmol/L primers (forward and reverse). Reaction conditions were: 94°C for 5 min, then 35 cycles at 94°C for 40 sec, 50°C for 40 sec, 72°C for 50 sec, followed by a final extension period of 7 min at 72°C.

**In vivo tumor-inhibitory experiments**

100 μl AFP-enhancing 4-element complex containing 0.2 μg pEBAF-as-preS2 DNA were injected into tumors of nude mice bearing hepatocarcinoma cells HepG2.2.15, once each week for 4 weeks and physiological salt solution was injected likewise in the control group. The diameters of tumors were measured every 3 days. Animals were sacrificed 1 week after the final injection. Tumor tissues were dissected and their diameters were measured.

**RESULTS**

**Construction of AFP-enhancing 4-element complex**

Polypeptide and plasmid were mixed in different ratios. According to the results of 1 % agarose gel electrophoresis, DNA was completely trapped at the slot with no DNA migration when the ratio was 1:1 (Figure 2). This is the optimal ratio of polypeptide to pEBAF-as-preS2 plasmid DNA.

**Extraction of total RNA**

Total RNA from all biopsies were analysed by Biophotometer.
(Eppendorf Co.). The ratios of A260 to A280 were all between 1.8 to 2.0. Using above total RNA as templates, RT-PCR were performed with primers for β-actin gene. A band of about 300bp in size was obtained in agarose gel electrophoresis (Figure 3A), proving that RNA was qualified for RT-PCR.

**Hepatocarcinoma directed expression of antisense RNA mediated by AFP-enhancing 4-element complex**

RT-PCR was carried out with specific primers (S2P1, S2P2) for HBpreS2 gene. 2 % gel electrophoresis demonstrated that the products of amplification could be detected only in tumor tissues of animals injected with AFP-enhancing 4-element complex. No specific bands could be tested in other tissues, especially in the epithelial cells of stomach mucosa and spermaduct. (Figure 3B).

**Figure 2** Construction of AFP-enhancing 4-element complex. 0.2 µg plasmid DNA was independently mixed dropwise with various quantity of polypeptide conjugation for 30 min at room temperature, and then the mixture was analyzed with 1 % agarose gel electrophoresis. Fig 2 showed the DNA retardation of different complex mixed with DNA and peptide in different ratios. The ratio of DNA and peptide in Lane 1 to 7 is 0, 1/1, 1/2, 1/2.5, 1/3, 1/3.5, 1/4. M indicates DNA marker.

**Figure 3** RT-PCR of tissues in nude mice treated AFP-enhancing 4-element complex. Total RNAs of different tissues of Nude mice bearing hepatocarcinoma were extracted 3 days after treatment with AFP-enhancing 4-element complex and then RT-PCR was performed; the expression of HBV preS2 gene was analyzed. A. RT-PCR of beta-actin. (bands 1 to 7 stand for the PCR products of spermaduct, stomach, liver, spleen, heart, and tumors, M stands for the DNA marker); B. RT-PCR of HBV preS2 gene.

**Inhibitory effects of AFP-enhancing 4-element complex on expression of HBV antigen in hepatocarcinoma cells**

In order to correct the results, the supernatants of cell cultures in all groups were collected before transfection, marked as P/N-0hr. The final results were calculated according to the following formula: antigen secretion of cells transfected with AFP-enhancing 4-element (tested)=\[\frac{P/N \text{ of tested}}{(P/N-0hr \text{ of tested}) \times (P/N-0hr \text{ of control})}\]. HBsAg and HBeAg expressions of HepG2.2.15 were lowered prominently after transfection with AFP-enhancing 4-element complex. The inhibitory rates were 33.4 % and 58.5 % respectively (Figure 4).

**Figure 4** Effect of AFP-enhancing 4-element complex on HBV gene expression in HepG2.2.15 cells.

**In vivo inhibitory effects of AFP-enhancing 4-element complex on growth of hepatocellular carcinoma in nude mice**

After 4 injections of AFP-enhancing 4-element complex containing 0.2 µg DNA, the diameter of tumor tissue was 0.995 cm±0.35, which was significantly smaller than that of the control groups (2.215 cm±0.25, P<0.05).

**DISCUSSION**

Hepatocellular carcinoma (HCC), especially HBV-associated HCC, is one of the most common malignant tumor in China. At present, there’s still no efficient therapy method\(^{[15-26]}\). Antisense nucleic acid, blocking the target gene and inhibiting its expression at the molecular level, has potential antiviral and antitumor effects\(^{[27-31]}\). In recent years, great interests have been focusing on such novel gene therapy. Compared with synthesized antisense DNA, antisense RNA could be expressed constantly in vivo, so that it has long-term antiviral effects. Thus, antisense RNA is an ideal choice in gene therapy for HBV\(^{[32-34]}\).

There are three crucial factors to determine the efficacy of antisense gene therapy\(^{[35]}\): whether the target gene plays a crucial role in tumorigenesis, whether it could be transected uniquely to target cells, and whether it could be expressed efficiently and specifically in those target cells. In this research, according to the characteristics of HBV-associated HCC, we selected preS2 which might play an important role in the pathogenetic targete site to be blocked. Moreover, in order to express preS2 antisense RNA strictly targeting on liver tumor cells, virus expression vector containing hepatocarcinoma-specific regulatory sequences (AFP promoter and enhancer) and EROP (HA20) combined with receptor mediated gene delivery system was prepared. The protein encoded by preS2 gene plays an important role in the infection as well as malignant transformation of HBV\(^{[36,37]}\). In a previous research, we have proved that synthesized antisense oligodeoxynucleotids (asON) against translation initiation region (3 203-3 219) of HBpreS2 has the strongest inhibitory effect on the expression of HBV antigen in HepG2.2.15 cells in vitro\(^{[38]}\). In addition, AS5, designed by Putlitz\(^{[33]}\) in this region, could efficiently inhibit the viral replication and the expression of HBV antigen. In this paper, preS2 gene (3 203-3 240nt) was selected as targete site for blocking by antisense RNA. Inhibitory experiments in vitro had demonstrated that a block of preS2 gene (3 203-3 240) could efficiently inhibited the expression of HBV antigen in HepG 2.2.15 cells. The inhibitory rates of the expression of HBsAg and HBeAg were 33.4 % and 58.5 % respectively.
The receptor-mediated gene delivery system transfers genes into the target cells by endocytosis via specific receptor. In 1998, Tian, Gu et al. (Shanghai Cancer Institute) established a novel high-efficiency receptor-mediated gene delivery system in which GE7 targeted on EGFR were used to transfer genes to tumor cells, and HA20 was synthesized as an EROP to enable the exogenous genes to escape from the lysosome. These properties guaranteed this system to have a significant potential in gene therapy.

However, the expression of EGFR is not limited to tumor cells. We have demonstrated that green fluorescence protein (GFP) reporter gene could be also expressed in the epithelial cells of stomach mucosa and spermaduct after being transfected with 4-element complex in vitro (published elsewhere).

For this reason, hepatocarcinoma tissue-specific antisense RNA expression vector under the control of AFP promoter was used to conjugate with GE7-PL and HA20-PL to construct an AFP-enhancing 4-element complex. As a specific marker for primary hepatocellular carcinoma, alfa fetal protein (AFP) possesses a high-targetable transcription-regulatory sequence which could be regulated precisely. Therefore, it could direct the therapeutic gene to be specifically expressed in AFP-positive hepatocellular carcinoma cells. Using human AFP incis element (promoter and enhancer) to control the expression of antisense RNA could not only enhance the high efficacy, but also possesses the targetability to hepatocellular carcinoma cells. Results showed that preS2 antisense RNA was only examined in tumor tissues of nude mice injected with AFP-enhancing 4-element complex but could not be examined in the epithelial cells of stomach mucosa and spermaduct either. Moreover, the growth of hepatocellular carcinoma in nude mice could be thwarted distinctively by being injected with AFP-enhancing 4-element complex at a dose equivalent of 0.2 μg DNA per mouse each time for 4 times.

In summary, this experiment showed that AFP-enhancing 4-element complex could deliver preS2 antisense RNA targeted on hepatoma cells and inhibited both HBV gene expression in vitro and tumor growth in vivo. All these results indicated the therapeutic potential of AFP-enhancing 4-element complex for HBV related HCC.

REFERENCES

1. Mah C, Fraites TJ Jr, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ. Improved Method of Recombinant AA2 Delivery for Systemic Targeted Gene Therapy. M ol Ther 2002; 6: 106-112
2. Zhang Y, Zhu C, Partridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. J Hepatol 2000; 32 (Suppl 1): 238-252
3. Lalwani AK, Jero J, Mhatre AN. Current issues in cochlear gene transfer. Audiol Neurootol 2002; 7: 146-151
4. Katz P, Shakhovsky MA, Jero J, Mhatre AN. Current issues in cochlear gene transfer. Audiol Neurootol 2002; 7: 146-151
5. Walker T, Shain U, Fichtner I, Voss C, Schmidt T, Schleef M, Nellessen T, Schlag PM. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. M ol Biol Cell 2002; 13: 105-115
6. Oupicky D, Ogris M, Seymour LW. Development of long-cirulating polylelectrolyte complexes for systemic delivery of genes. J Drug Target 2002; 10: 93-98
7. Richards P, Kren BT, Steer CJ. In vivo application of non-viral vectors to the liver. J Drug Target 2002; 10: 123-131
8. Yaghamal R, Cutting GR. Optimized regulation of gene expression using artificial transcription factors. M ol Ther 2002; 5: 685-694
9. Wnt Y, Wilson JM, Slaby F, Grossman M, Shafritz DA, Wu W. Receptor mediated gene delivery in vivo: partial correction of genetic anabulinemia in a nagase rats. J Biol Chem 1991; 266: 14338-14342
10. Huber BE, Richards CA, Krenitsky TA. Retrouval mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1993; 88: 8039-8043
11. Sato Y, Tanaka K, Lee G, Kanegaue Y, Sakai Y, Kaneko S, Nakabayashi H, Tamaoki T, Saito I. Enhanced and specific gene expression via tissue-specific production of cre recombinase using adenovirus vector. Biochem Biophys Res Commun 1998; 244: 455-462
12. Brand K, Loser PA, Rnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 1998; 5: 1363-1371
13. Tian PK, Ren SJ, Ren CC, Teng QS, Qu SM, Yao M, Gu J. A novel receptor-targeted gene delivery system for gene therapy. Zhongguo Kexue (Series C) 1998; 28: 554-558
14. Ono Y, Onda H, Sasaoda R, Igarashi K, Sugino Y, Nishiola K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983; 11: 1747-1757
15. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366
16. Lau GK. Hepatitis B infection in China. Clin Liver Dis 2001; 5: 361-379
17. Merican I, Guan R, Amarapu B, Alexander MJ, Chuatputti A, Chin RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjafloël Noer HM, Soliano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-1361
18. Zhan GL, You J, Tang BZ, Ding SY, Yan K, Peng D, Zhang YM, Zhang L. Preliminary results of Thyminos-E3 versus interferon-α treatment in patient with HBsAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2003; 9: 407-410
19. Xie Q, Guo Q, Zhou XQ, Gu, RY. Effect of adriamycin on duck hepatitis B virus. Shijie Huaren Xiàzhi 1999; 7: 125-126
20. Li J, Tang B. Effect on replication of hepatitis B virus by Chinese traditional medicine. Shijie Huaren Xiàzhi 2000; 8: 945-946
21. Xu CT, Pan BR. Current status of gene therapy in gastroenterology. World J Gastroenterol 1998; 4: 85-89
22. Xu KC, Wei BH, Yao XX, Zhang WD. Recently therapy for chronic hepatitis B virus by combined Traditional Chinese and Western medicine. Shijie Huaren Xiàzhi 1999; 7: 970-974
23. Lau R. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15 (Suppl): E46-52
24. Guan R. Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000; 15 (Suppl): E34-40
25. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118 (2 Suppl 1): S83-103
26. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2003; 120: 1000-1008
27. Feng RH, Zhu ZG, Li JF, Liu BY, Yan M, Yin HR, Lin YZ. Inhibition of human telomerase in MKN-45 cell line by antisense hTR expression vector induces cell apoptosis and growth arrest. World J Gastroenterol 2002; 8: 436-440
28. Nie QH, Cheng YQ, Xie YM, Zhou YX, Cao YZ. Inhibiting effect of antisense oligonucleotides phosphorothioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol 2002; 7: 363-369
29. Wang XW, Yuan JH, Zhang RG, Guo LX, Xie Y, Xie H. Antihematoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice. World J Gastroenterol 2001; 7: 345-351
30. Yabata N, Kyo S, Kondo S, Kanaya T, Wang Z, Mida Y, Takakura M, Nakamura M, Tanaka M, Inoue M. 5-ASA antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 2002; 9: 624-630
31. Yang S, Fang D, Liu A, Yang J, Luo Y, Lu R, Liu W. Reversing malignant phenotypes of liver cancer cell lines with antisense gene to human telomerase reverse transcriptase. Zhonghua
Ganzangbing Zazhi 2002; 10: 97-99
32 Wu J, Gerber MA. Gerber. The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis. J General Virol 1997; 78: 641-647
33 zu Putlitz J, Wieland S, Blum HE, Wands Jr. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 1998; 115: 702-713
34 Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 1996; 56: 1098-1103
35 Wang S, Dolnick BJ. Quantitative evaluation of intracellular sense: antisense RNA hybrid duplexes. Nucleic Acids Res 1993; 21: 4383-4391
36 Neurath AR, Strick N, Sproul P. Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exe Med 1992; 175: 461-469
37 Alka S, Hemlata D, Vaishali C, Shahid J, Kumar PS. Hepatitis B virus surface (S) transactivator with DNA-binding properties. J Med Virol 2000; 61: 1-10
38 Ma CH, Sun WS, Liu SX, Ding PF, Zhang LN, Cao YL, Song J. Comparison of the anti-HBV effect of various antisense oligodeoxynucleotides. Zhonghua Weisheng Wuwue Yu Mianyixue Zazhi 2000; 20: 12-14
39 Watanabe K, Saito A, Tamaoki T. Cell-specific enhance activity in far upstream region of the human alpha-fetoprotein gene. J Biol Chem 1987; 262: 4812-4818

Edited by Lu HM